First-in-Human Trial

Matricelf Gains FDA Feedback for NewRal Spinal Injury Trial

Ness Ziona, Israel, September 3, 2026 Matricelf Ltd., a regenerative medicine company developing personalized engineered tissue therapies, has received...

By cGxPwire Editor
September 8, 2026

.Clinical

Polyrizon Advances NASARIX™ Toward First-in-Human Trial

RAANANA, Israel, July 2, 2026 Polyrizon Ltd. announced the successful completion of its NASARIX™ biocompatibility evaluation program, marking an...

By cGxPwire Editor
July 6, 2026

.Clinical

Mondego Bio Names PTPN2 Inhibitor for First-in-Human Study

CANTANHEDE, Portugal — December 22, 2025 — Mondego Bio has announced the formal selection of ZE00-0388, a highly selective...

By cGxPwire Editor
December 23, 2025

.Clinical Bio-Pharma

Anixa Biosciences Completes Final Patient Visit in Breast Cancer Vaccine Trial

SAN JOSE, Calif., October 7, 2025 – Anixa Biosciences, Inc. (NASDAQ: ANIX), a clinical-stage biotechnology company dedicated to cancer...

By cGxPwire Editor
October 7, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

First-in-Human Trial

Matricelf Gains FDA Feedback for NewRal Spinal Injury Trial

Polyrizon Advances NASARIX™ Toward First-in-Human Trial

Mondego Bio Names PTPN2 Inhibitor for First-in-Human Study

Anixa Biosciences Completes Final Patient Visit in Breast Cancer Vaccine Trial